生物制品行业跟踪报告：血制品2024H1综述，血制品行业稳健增长，行业整合加速

Investment Rating - The industry investment rating is "Outperform the Market" with an expectation of over 10% relative increase in the industry index compared to the market in the next six months [31]. Core Insights - The blood products industry is experiencing steady growth, with listed companies showing robust financial performance and plasma collection volume. The industry is undergoing accelerated consolidation through mergers and acquisitions [1][3]. - The demand for blood products is expected to increase due to the growing elderly population, particularly in first-tier cities, leading to market expansion. Additionally, there is significant room for improvement in per capita consumption of blood products in China compared to international levels [26]. - The supply side has seen a steady increase in the number of plasma collection stations and plasma collection volume over the past few years, with several provinces launching construction plans for plasma stations [26]. Summary by Sections Blood Product Stock Review - Over the past year (September 7, 2023, to September 6, 2024), the blood products sector (Shenwan) increased by 10.65%, outperforming the pharmaceutical and biological sector by 30.05 percentage points and the CSI 300 index by 24.67 percentage points [7][9]. - Among the six listed blood product companies, the highest absolute increase was seen in Palin Biological (+50.17%), followed by Tiantan Biological (+32.35%) and Boya Biological (+27.96%) [9]. Blood Product 2024H1 Performance Overview - In 2024H1, companies such as Palin Biological, Shanghai Laisai, Weiguang Biological, and Tiantan Biological reported year-on-year growth in both operating revenue and net profit attributable to shareholders [13][14]. - The plasma collection volume for the first half of 2024 showed double-digit year-on-year growth for all companies that disclosed their data, with Palin Biological collecting 700 tons (+27.27%) and Tiantan Biological 1294 tons (+15.02%) [15][17]. Mergers and Acquisitions in Blood Product Companies - The blood products industry has a high entry barrier due to strict regulatory policies, leading to accelerated consolidation through mergers and acquisitions. Currently, there are about 30 operational blood product manufacturers in China, with the number expected to decrease as consolidation continues [19][26]. - Recent acquisition cases include Boya Biological acquiring Hong Kong Red Cross and Tiantan Biological acquiring Zhongyuan Ruide [19][20]. Analysis of Unlisted Blood Product Manufacturers - The report identifies several unlisted blood product manufacturers based on batch issuance data, with Shandong Taibang having the most records across various products [23][24]. Investment Recommendations - The report suggests that the blood products sector has high entry barriers and is likely to see increased concentration through mergers. It recommends focusing on companies like Tiantan Biological, Boya Biological, and Palin Biological due to their competitive advantages in plasma resource acquisition and R&D capabilities [26].